Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PEGylated human IL-10 (AM0010) in Combination with an anti-PD-1 in Advanced NSCLC (9PD)

Date

09 Dec 2017

Session

Poster Discussion session

Presenters

Deborah Wong

Citation

Annals of Oncology (2017) 28 (suppl_11): xi3-xi5. 10.1093/annonc/mdx710

Authors

D. Wong1, J.G. Schneider2, R. Aljumaily3, W..M. Korn4, J. Infante5, M. Patel6, K. Autio7, K. Papadopoulos8, A. Naing9, N.Y. Gabrail10, P. Munster11, J. Goldman1, N. Ratti12, P. Van Vlasselaer13, A. Hung12, M. Oft12, E. Garon14

Author affiliations

  • 1 Medicine, Hematology/oncology, UCLA - School of Medicine, 90095 - Los Angeles/US
  • 2 Oncology, Winthrop University Hospital, Mineola/US
  • 3 Cancer Center, OUHSC, Oklahoma City/US
  • 4 Cancer Center, UCSF-Diller Cancer Research Building, Mount Zion, 94115 - San Francisco/US
  • 5 Oncology, Sarah Cannon Research Institute-cancer centre, 37203 - Nashville/US
  • 6 Oncology, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota/US
  • 7 Gu-immunotherapeutics, MSKCC, New York/US
  • 8 Oncology, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 9 Investigational Therapeutics, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 10 Cancer Center, Gabrail Cancer Center, Canton/US
  • 11 Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 12 Clin Development, ARMO BioSciences, 94063 - Redwood City/US
  • 13 Corp, ARMO BioSciences, 94063 - Redwood City/US
  • 14 Medicine: Hem/onc, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US
More

Resources

Background

At therapeutic concentrations, PEGylated IL-10 (AM0010) stimulates the cytotoxicity, survival and proliferation of intratumoral antigen activated CD8+ T cells in pre-clinical cancer models and in patients. AM0010 activates antigen stimulated CD8 T cells while PD-1 inhibits them, providing a rationale for combining AM0010 with PD-1 inhibitors.

Methods

34 NSCLC pts received AM0010 (10-20ug/kg QD, SC) with pembrolizumab (2mg/kg, q3wk IV; n = 5) or nivolumab (3mg/kg, q2wk IV; n = 29). Pts had a median of 2 prior therapies. The median follow-up is 14.9 mo (range 5.6-30.3). Tumor responses were assessed by irRC. 20 patients were analyzed for PD-L1 expression (22C3). Immune responses were measured by analysis of serum cytokines (Luminex), activation of blood derived CD8 T cells (FACS) and peripheral T cell clonality (TCR sequencing). Tumor tissue was analyzed for tumor mutational burden by WES and mRNA expression of IO markers (Nanostring).

Results

AM0010 plus anti-PD-1 was well tolerated. All TrAEs were reversible and transient. G3/4 TrAEs included thrombocytopenia (8), anemia (7), fatigue (6), rash (4), pyrexia (2), hypertriglyceridemia (3) and pneumonitis (1). As of Sept 15, 2017, 27 pts had at least 1 tumor assessment. 10 pts (36.4%) had a partial response (PR) and 12 pts (44.4%) had stable disease (SD). Notably, of five patients with PD-L1 + ≥ 50% NSCLC, four had a PR, 1 had SD with 47% reduction of tumor burden.Table: 9PD

Preliminary response data stratified for PD-L1

NSCLC (n = 27)PD-L1 (22C3 IHC) (n = 20)IHC not available n = 6

Conclusions

AM0010 in combination with an anti-PD-1 is well-tolerated in advanced NSCLC pts. The improved efficacy regardless of PD-L1 status and the observed CD8 T cell activation is promising and encourages the continued study of AM0010 in combination with an anti-PD-1.

Clinical trial identification

NCT02009449

Legal entity responsible for the study

ARMO BioSciences

Funding

ARMO BioSciences

Disclosure

N. Ratti, A. Hung, M. Oft: Employee of ARMO BioSciences. P. Van Vlasselaer: Employee and stock owner of ARMO BioSciences. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.